Epinephrine
1mg/1ml ampoules (IV, IM, IO, nebulization, subcutaneous)
Executive Summary
(February 2023)
Epinephrine is an endogenous catecholamine non-selective agonist of all adrenergic receptors with a major role in emergency medicine on a variety of different diagnoses.
Anaphylaxis
Epinephrine acts on several pathophysiological pathways that cause anaphylaxis. To this date, it is the only established therapy to treat this condition with a proven efficacy (1, 3, 4).Cardiac arrest
Current guidelines include epinephrine as part of standard treatment during cardiac arrest in children and adults, being the only recommended drug regardless of initial rhythm (10, 11) mainly because it is associated with an increased rate of ROSC* and short-term survival (6, 7, 8, 13). Benefits of epinephrine predominate in an early administration (<10 minutes) of non-shockable cardiac arrest (12, 13).Severe asthma crisis
Consider IV or IM epinephrine in the crashing asthmatic patient to deliver a systemic Beta-2 agonist agent (when inhaled bronchodilators have trouble getting into the lower airway). Give as a push-dose if administered IV, and an equivalent anaphylaxis dose for IM administration.
*ROSC: Return of Spontaneous Circulation
Adult dose for anaphylaxis
0.01mg/kg (max 0.5mg per dose) IM into the anterolateral aspect of the thigh.
Can be repeated every 5-15 min if necessary.
If no response, consider a continuous IV infusion of epinephrine.
Adult dose for cardiac arrest
1mg every 3 to 5 minutes IV or IO.
In shockable rhythms early defibrillation should be perform as soon as possible, before any other resuscitation interventions.
Indications
FDA-Labeled (5)
Hypotension associated with septic shock (norepinephrine is preferred as first-line medication)
Off-label
Cardiac arrest
Symptomatic AV heart block unresponsive to atropine
Croup (alternative to nebulized racepinephrine)
Severe asthma
Epistaxis (topical, diluted)
Adult dose
Anaphylaxis (3)
Adult dose for anaphylaxis
0.01mg/kg (max 0.5mg per dose) IM into the anterolateral aspect of the thigh.Can be repeated every 5-15 min if necessary.
If there is no response, consider a continuous IV infusion of epinephrine.
Cardiac Arrest (10)
Adult dose for cardiac arrest
1mg every 3 to 5 minutes IV or IO.In shockable rhythms early defibrillation should be performed as soon as possible, before any other resuscitation interventions.
Crashing asthmatic
Adult dose for the crashing asthmatic
IV: consider use as push-dose epinephrine (50-100ug every 5-10 min).
IM: 0.01mg/kg (max 0.5mg per dose) into the anterolateral aspect of the thigh.
Pediatric dose
Anaphylaxis (3)
Pediatric dose for anaphylaxis
0.01mg/kg (max 0.3mg per dose) IM into the anterolateral aspect of the thigh.Can be repeated every 5-15 min if necessary.
If there is no response, consider a continuous IV infusion of epinephrine.
Cardiac Arrest (11)
Pediatric dose for cardiac arrest
0.01mg/kg every 3 to 5 minutes, IV or IO
0.1mg/ml concentration, max 1mg per doseIn shockable rhythms early defibrillation should be performed as soon as possible, before any other resuscitation interventions
Crashing asthmatic
Pediatric dose for the crashing asthmatic
IV: 0.5-1ug/kg, repeat every 5-10 min if necessary
IM: 0.01mg/kg (max 0.3mg per dose) into the anterolateral aspect of the thigh, repeat every 5-15 min if necessary
Pathophysiology of anaphylaxis: epinephrine role
As a non-selective adrenergic agonist, epinephrine increases peripheral vascular resistance through vasoconstriction and has chrono-inotropic effects in order to increase cardiac output (3). Epinephrine antagonizes the consequences of anaphylaxis-mediated cardiovascular collapse, soft tissue edema (that leads to gastrointestinal symptoms and airflow obstruction secondary to upper and lower respiratory tract compromise), as well as the release of other inflammatory mediators.
Antihistamines (ATH) and glucocorticoids (GCs) are almost universally prescribed for anaphylaxis and other allergic reactions, but have a longer onset of action, and their pharmacological target does not antagonize anaphylaxis pathophysiology.
ATH may treat urticaria and itching, improving symptoms during anaphylaxis (3).
ATH and GCs are not recommended as first-line therapy that could delay epinephrine administration (3).
ATH and GCs utility as adjuncts is questionable on whether to treat the main episode and to prevent biphasic anaphylaxis (3).
The effects of epinephrine can divided by receptor functions (2):
𝛼-1 (alpha-1) peripheral receptors
Increases vasoconstriction, increasing systemic vascular resistance.
Reduces upper airway edema, mucosal and peripheral edema.
β1/ β2 (beta-1 and beta-2) cardiac receptors
Increases cardiac output by increasing inotropism and chronotropism. The α-1 vasoconstrictor effect has a major impact on systemic vascular resistance than b2-peripheral receptor activation.
β2 (beta-2) bronchial receptors
Produces bronchodilation by smooth muscle relaxation.
β2 (beta-2) Lymphocyte receptor (present in mast cells and basophils)
Reduces degranulation of inflammatory cells and histamine release.
In anaphylaxis, stimulation of mast cells and basophils release inflammatory mediators such as histamine, producing vasodilation, cardiac depression (as mast cells are present through the myocardium and the intima of coronary arteries) and finally cardiovascular collapse.
Current concerns about epinephrine in cardiac arrest
In recent years, epinephrine utility has been questioned because of conflicting data on long term survival and its association with detrimental neurological outcomes (7, 9).
2020 Adult Advanced Life Support Guidelines state the following (10):
“Concerns have been expressed about epinephrine increasing the number of survivors with unfavorable neurological outcome in the PARAMEDIC2 trial (Pre-Hospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug Administration in Cardiac Arrest).
The opinion of the ALS Task Force, however, is that any drug that increases the rate of ROSC and survival, but is given after several minutes of cardiac arrest when some degree of neurological damage may already have occurred, will likely increase the number of survivors with both favorable and unfavorable neurological outcome. Determining the likelihood of favorable or unfavorable neurological outcome at the time of starting resuscitation is currently not feasible. Therefore, the task force consensus is that continuing to use a drug that increases survival and focusing efforts on providing earlier CPR, earlier drug administration, and improved post-resuscitation care for all patients is likely to increase survival with a favorable neurological outcome.”
PARAMEDIC-2 compendium available at The Bottom Line - PARAMEDIC2
Must-read articles
Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020;145(4):1082-1123. doi:10.1016/j.jaci.2020.01.017
Pubmed
Cardiac Arrest Advanced Cardiovascular Life Support
Adults
Berg KM, Soar J, Andersen LW, et al. Adult Advanced Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2020;142(16_suppl_1):S92-S139. doi:10.1161/CIR.0000000000000893
AHA-Circulation (Open Access)Text extract:
"Treatment Recommendations
We recommend administration of epinephrine during CPR (strong recommendation, low to moderate certainty of evidence).
For nonshockable rhythms (pulseless electric activity/asystole), we recommend administration of epinephrine as soon as feasible during CPR (strong recommendation, very low-certainty evidence).
For shockable rhythms (VF/pVT), we suggest administration of epinephrine after initial defibrillation attempts are unsuccessful during CPR (weak recommendation, very low-certainty evidence)."
Pediatrics
Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020;142(16_suppl_2):S469-S523. doi:10.1161/CIR.0000000000000901
AHA-Circulation (Open Access)
References
Anaphylaxis
Campbell RL, Li JT, Nicklas RA, Sadosty AT; Members of the Joint Task Force; Practice Parameter Workgroup. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. Ann Allergy Asthma Immunol. 2014;113(6):599-608. doi:10.1016/j.anai.2014.10.007
Pubmed
Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13th edition. McGraw Hill; 2017.
McGraw-HillShaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020;145(4):1082-1123. doi:10.1016/j.jaci.2020.01.017
Pubmed
McHugh K, Repanshek Z. Anaphylaxis: Emergency Department Treatment. Emerg Med Clin North Am. 2022 Feb;40(1):19-32. doi: 10.1016/j.emc.2021.08.004. Epub 2021 Oct 29. PMID: 34782088.
PubmedNIH-NLM (National Institutes of Health National Library of Medicine). DailyMed. Label: Adrenalin - epinephrine injection. Updated in December 2022. Accessed in February 2023.
DailyMed
Cardiac arrest
Olasveengen TM, Wik L, Sunde K, Steen PA. Outcome when adrenaline (epinephrine) was actually given vs. not given - post hoc analysis of a randomized clinical trial. Resuscitation. 2012;83(3):327-332. doi:10.1016/j.resuscitation.2011.11.011
PubmedLoomba RS, Nijhawan K, Aggarwal S, Arora RR. Increased return of spontaneous circulation at the expense of neurologic outcomes: Is prehospital epinephrine for out-of-hospital cardiac arrest really worth it?. J Crit Care. 2015;30(6):1376-1381. doi:10.1016/j.jcrc.2015.08.016
PubmedShao H, Li CS. Epinephrine in Out-of-hospital Cardiac Arrest: Helpful or Harmful?. Chin Med J (Engl). 2017;130(17):2112-2116. doi:10.4103/0366-6999.213429
PubmedPARAMEDIC-2: Perkins GD, Ji C, Deakin CD, et al. A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest. N Engl J Med. 2018;379(8):711-721. doi:10.1056/NEJMoa1806842
NEJM (Open Access)Berg KM, Soar J, Andersen LW, et al. Adult Advanced Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2020;142(16_suppl_1):S92-S139. doi:10.1161/CIR.0000000000000893
AHA-Circulation (Open Access)Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020;142(16_suppl_2):S469-S523. doi:10.1161/CIR.0000000000000901
AHA-Circulation (Open Access)Okubo M, Komukai S, Callaway CW, Izawa J. Association of Timing of Epinephrine Administration With Outcomes in Adults With Out-of-Hospital Cardiac Arrest. JAMA Netw Open. 2021;4(8):e2120176. Published 2021 Aug 2. doi:10.1001/jamanetworkopen.2021.20176
Pubmed Central (Open Access)Fernando SM, Mathew R, Sadeghirad B, et al. Epinephrine in Out-of-Hospital Cardiac Arrest - A Network Meta-Analysis and Subgroup Analyses of Shockable and Non-Shockable Rhythms [published online ahead of print, 2023 Jan 31]. Chest. 2023;S0012-3692(23)00165-4. doi:10.1016/j.chest.2023.01.033
Pubmed
DISCLAIMER
⚠ This website provides general information and discussion about medications, health, and related subjects. The words and other content provided in this website, and in any linked materials, are not intended and should not be construed as medical advice. If the reader or any other person has a medical concern, he or she should consult with an appropriately-licensed physician or other legally accredited health care worker in the country that resides or is visiting.
Please do not delay your medical concerns and potential health emergencies by searching information in this website, instead look out for medical opinion in the services that exist with that specific purpose and work under the respective local health-care regulations.
The views expressed on this blog and website have no relation to those of any academic, hospital, practice or other institution with which the authors are affiliated.
For other instances, the authors of this website do not have any conflict of interest with any institution or pharmaceutical company in particular, and do not receive any compensation about any licenced drug mentioned in the website. In the same matter, the website is not intended to recommend any specific patented medication.
EMDrugs Team